Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc, dated August 23, 2024, reports a specific corporate action rather than periodic financial results. Haleon is a global leader in consumer health with a portfolio spanning Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS). The filing details a transaction in own shares executed under a share buyback programme announced on August 1, 2024.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 700,000 ordinary shares
- Price Range: Lowest 369.60 pence; Highest 372.40 pence
- Volume Weighted Average Price: 370.8951 pence
- Post-Transaction Share Capital: 9,125,585,552 ordinary shares
Material Changes
The material change reported is the reduction of the company's registered share capital following the cancellation of 700,000 shares. This transaction is part of the ongoing Buyback Programme. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
This filing contains no management guidance, outlook, or discussion of risks and contingencies. It is a regulatory disclosure of a completed trade. The text notes that a full breakdown of individual trades is available via the London Stock Exchange and the company's investor website.
Investor Verification Checklist
- Verify the total number of shares repurchased to date under the August 1, 2024 Buyback Programme.
- Confirm the updated total share capital of 9,125,585,552 shares for disclosure threshold calculations.
- Review the full trade breakdown at the provided RNS link for intraday pricing details.
- Check the company's website for the latest financial results, as this filing does not contain performance data.